Advertisement
For patients receiving anti-epidermal growth factor receptor treatment

Prophylactic Antibiotics Cut Risk of Anti-EGFR Skin Rash

0
Systematic review shows reduction in risk of developing a skin rash with prophylactic antibiotics
There is more evidence linking air pollution with increased risk of developing hypertension

More Evidence That Air Pollution Raises Blood Pressure

0
Hypertension risk up for both short-term and long-term exposure
Only half of parents of children with asthma fully understand the use of their child's asthma medications

Many Parents Know Too Little About Their Child’s Asthma Meds

0
Only half surveyed knew what drugs were prescribed, how to use them
Receipt of influenza vaccination may reduce heart failure patients' risk of hospitalization

Flu Vaccine Can Help Keep Heart Failure Patients Out of Hospital

0
Vaccination tied with lower risk of hospitalization for cardiovascular diseases, respiratory infections
Betrixaban may be beneficial versus enoxaparin in acutely ill medical patients

Possible Benefit Found for Betrixaban in Acutely Ill

0
No significant difference versus enoxaparin in prespecified primary efficacy outcome
Ocaliva (obeticholic acid) has been approved by the U.S. Food and Drug Administration to treat primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA

FDA Approves Ocaliva for Primary Biliary Cholangitis

0
For patients who have not responded to, or cannot tolerate, ursodeoxycholic acid
A new communication toolkit created by the Agency for Healthcare Research and Quality can help health care organizations and providers communicate with patients and families when harm occurs to patients.

AHRQ Communication Toolkit Can Help After Patient Harm Occurs

0
Toolkit helps patients, families, clinicians, and administrators discuss what happened
For patients receiving cephalexin monotherapy for non-purulent cellulitis

Cephalexin Failure Rate Similar for Morbidly Obese, Non-Obese

0
No difference in rate of therapeutic failure for morbidly obese, non-obese patients with cellulitis
A decision tool (dual antiplatelet therapy [DAPT] score) improves risk prediction for continued DAPT beyond assessment of myocardial infarction history

DAPT Score Improves Risk Prediction of Continued DAPT

0
Score improves prediction of benefit and harm for continued DAPT therapy beyond MI history alone
For patients with rheumatoid arthritis

Glucocorticoid Use Ups Diabetes Risk in Rheumatoid Arthritis

0
Risk influenced by dosage and duration of treatment for glucocorticoid use in past six months